P-glycoprotein is an ATP (adenosine triphosphate)-driven drug efflux transporter that is
highly expressed at the blood–brain barrier (BBB) and is a major obstacle to the …

The ATP-driven drug efflux pump, P-glycoprotein, is a critical and selective element of the
blood-brain barrier and a primary impediment to pharmacotherapy of central nervous system …

Pharmacotherapy of central nervous system (CNS) disorders (eg, neurodegenerative
diseases, epilepsy, brain cancer, and neuro-AIDS) is limited by the blood-brain barrier. P …

At the blood-brain barrier, P-glycoprotein, an ATP-driven drug efflux pump, selectively limits
drug access to the brain parenchyma, impeding pharmacotherapy of a number of central …

The central nervous system (CNS) effects of many therapeutic drugs are blunted because of
restricted entry into the brain. The basis for this poor permeability is the brain capillary …

Upregulation of blood-brain barrier (BBB) P-glycoprotein expression causes central nervous
system (CNS) pharmacoresistance. However, activation of BBB protein kinase C-β1 (PKC …

P-glycoprotein (P-gp) is known to transport a diverse array of xenobiotics, including
therapeutic drugs. A member of the ATP-binding cassette (ABC) transporter family, P-gp is a …

The blood–brain barrier is a microvascular network that (1) provides neuroprotection from
metabolic and environmental toxins and (2) limits the delivery of therapeutics to the central …

The purpose of this study was to investigate the modification of expression and functionality
of the drug transporter P-glycoprotein (P-gp) by tumor necrosis factor-alpha (TNF-α) and …

Increased expression of drug efflux transporters at the blood-brain barrier accompanies
epileptic seizures and complicates therapy with antiepileptic drugs. This study is concerned …